Today, pharmaceutical manufacturers have very high expectations for the contribution of precise 3D structural information regarding proteins and their complexes that may be obtained using ultra-brilliant synchrotron radiation. These expectations relate to their drug discovery process and to the promise of the actual discovery of innovative drugs in the future.
